From broad executive orders and tariff threats to individual corporate pricing deals, pharma companies have found themselves in a reactive stance this year, trying to keep up with volatile, shifting ...

At PSE&G, we invested approximately $1 billion in the quarter and $2.7 billion over the first 9 months of 2025, all part of our planned full year $3.8 billion regulated capital spending program ...

Wheelchairs are a clear example of the gap. Reid noted that a properly fitted wheelchair must be selected in consultation ...